Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab

Arthritis Care and Research

Volumn 61, Issue 12, 2009, Pages 1762-1764

  Tanaka, Toshio ^a   Kuwahara, Yusuke ^a   Shima, Yoshihito ^a   Hirano, Toru ^a   Kawai, Mari ^a   Ogawa, Masako ^a   Arimitsu, Junsuke ^a   Hagihara, Keisuke ^a   Narazaki, Masashi ^a   Ogata, Atsushi ^a   Kawase, Ichiro ^a   Kishimoto, Tadamitsu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; SERUM AMYLOID A; STROMELYSIN; TOCILIZUMAB;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; JOINT SWELLING; REACTIVE ARTHRITIS; SYMPTOM; TREATMENT RESPONSE; URETHRITIS; VISUAL ANALOG SCALE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, REACTIVE; CITRATES; FEMALE; GALLIUM; HEALTH STATUS; HUMANS; JOINTS; RADIONUCLIDE IMAGING; RECEPTORS, INTERLEUKIN-6; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73449141147     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24899     Document Type: Article

References (15)

1. Wu IB, Scwartz RA. Reiter's syndrome: the classic triad and more. J Am Acad Dermatol 2008;59:113-21.
2. Toivanen A, Toivanen P. Reactive arthritis. Best Pract Res Clin Rheumatol 2004;18:689-703.
3. Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 2004;17:348-69.
4. Palazzi C, Olivieri I, D'Amico E, Pennese E, Petricca A. Management of reactive arthritis. Expert Opin Pharmacother 2004; 5:61-70.
5. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 2003;30:407-11.
6. Gill H, Majithia V. Successful use of infliximab in the treatment of Reiter's syndrome: a case report and discussion. Clin Rheumatol 2008;27:121-3.
7. Oili KS, Niinisalo H, Korpilahde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scand J Rheumatol 2003;32: 122-4.
8. Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR Jr. Decreased pain and synovial inflammation after etan-ercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 2005;53:613-7.
9. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369: 1379-90.
10. Kishimoto T. Interleukin-6: from basic science to medicine. 40 years in immunology. Annu Rev Immunol 2005;23:1-21.
11. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003;21 Suppl 2:S24-34.
12. Metsarinne KP, Nordstrom DC, Konttinen YT, Teppo AM, Fyhrquist FY. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 1992;12:93-6.
13. Straub RH, Paimela L, Peltomaa R, Scholmerich J, Leirisalo-Repo M. Inadequately low levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002;46:654-62.
14. Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondylo-arthropathy. J Rheumatol 2007;34:2285-90.
15. Mihara M, Ohsugi Y, Kishimoto T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interleukin-6 receptor antibody. Biofactors 2009; 35:47-51.